A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma

Published:2023-05-03 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Noel Robin¹^ORCID,Zemmour Christophe²³,Montes de Oca Catalina¹,Belmecheri Nawel¹,Aurran-Schleinitz Thérèse¹,Coso Diane¹,Lopez Almeida Leonor⁴,Mescam Lénaïg⁵,Vey Norbert⁶^ORCID,Bladé Jean Sébastien⁷,Slama Borhane⁸,Bouabdallah Reda¹,Schiano de Colella Jean-Marc¹

Affiliation:

1. Department of Hematology, Institut Paoli-Calmettes, Marseille, France

2. Department of Clinical Research and Innovation – Biostatistics & Methodology Unit, Marseille, France

3. Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France

4. Department of Clinical Research and Innovation – Sponsoring Unit, Institut Paoli-Calmettes, Marseille, France

5. Department of Pathology, Institut Paoli-Calmettes, Marseille, France

6. Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France

7. Department of Oncology and Hematology, Sainte Anne Military Hospital, Toulon, France

8. Department of Hematology, Centre Hospitalier Raoul Follereau, Avignon, France

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2207948

Reference22 articles.

1. Diffuse Large B-Cell Lymphoma

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

3. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

4. Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

5. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype